“Adding low-dose cyclophosphamide to lenalidomide and prednisone is an active oral combination regimen among patients with multiple myeloma refractory to lenalidomide…”
You are a Multiple Myeloma patient who’s disease has become refractory to lenalidomide. The article linked an excerpted below talks about adding cytoxan (cyclophosphamide) and prednisone to increase response rates in multiple myeloma patients who are refractory to lenalidomide.
I’ve taken cytoxan and I can tell you that this chemo can bring real problems particularly a side effect called hemoragic cystitis. Please supplement with omega-3 fatty acids to minimize this painful long-term side effect.
Further, I developed chronic A-fib (heart damage) in the fall of 2010. I can’t prove that my heart damage was caused by the cytoxan therapy but if I knew then what I know now I would supplement with green tea extract.
I am a long-term myeloma survivor and MM cancer coach. The two most important things to remember about MM is 1) there is a long and growing list of FDA approved chemotherapy regimens for MM and 2) there is a long and growing list of evidence-based, non-toxic, anti-MM therapies.
MM is sort of like playing Whac-a-Mole. You will smack your MM until it hides… for awhile. And your MM will pop up again months or maybe even years later. And you will whac it again. If you can minimize the toxicity you can do this whac-ing for decades.
Minimize your toxicity by adding evidence-based, non-toxic therapies to your whacking.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
https://youtu.be/ctekyVc9yGc
Write a post below if you would like the
- the questions guide
- and/or the integrative therapies guide
If you would like to ask me a question about your myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.
Thank you,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Recommended Reading:
“Adding low-dose cyclophosphamide to lenalidomide and prednisone is an active oral combination regimen among patients with multiple myeloma refractory to lenalidomide, according to a study published in Blood.1…
Among the 67 patients treated with maximum tolerated dose, the overall response rate was 67%; 83% achieved at least a minimal response. Median progression-free survival and overall survival were 12.1 months and 29.0 months, respectively….
Similar findings were observed among patients with disease refractory to both lenalidomide and bortezomib, as well as among patients with high-risk cytogenetic abnormalities…
The most common adverse events were hematologic toxicities, including grade 3 to 4 neutropenia in 22% of patients, grade 3 anemia in 4%, and grade 3 to 4 thrombocytopenia in 17%. The most frequently reported non-hematologic toxicity was infection, which included mostly upper and lower respiratory tract infections.
The findings suggest that continuous low-dose cyclophosphamide with lenalidomide and prednisone is a potential multidrug therapeutic strategy for patients with refractory multiple myeloma.”
APPIP ERROR: amazonproducts[
AccessDeniedAwsUsers|The Access Key Id AKIAJAJ37JVNL7OUU4CA is not enabled for accessing this version of Product Advertising API. Please migrate your credentials as referred here https://webservices.amazon.com/paapi5/documentation/migrating-your-product-advertising-api-account-from-your-aws-account.html.
]
